Analysis of new immunohistochemical biomarkers in a cohort of pancreatic NETs

#4617

Introduction: Pancreatic neuroendocrine tumours (PanNETs) are rare diseases with a 10-year survival rate of only 40-50%. The ATRX, DAXX and ARX, PDX1 expressions in PanNETs were considered poor prognostic factors in some studies, but inconsistent in others.

Aim(s): The aim of our study was to evaluate the ATRX, DAXX, ARX and PDX1 expression and explore if they can stratify PanNETs patients.

Materials and methods: The samples of 58 surgically resected primary PanNETs in three Romanian centres from January 2005 to December 2023 were collected retrospectively, and ATRX, DAXX, ARX/PDX1 immunohistochemistry on PPFE were performed. Their expression was compared with various clinicopathologic factors.

Conference:

Presenting Author:

Authors: Ciobanu O, Martin S, Herlea V, Vasilescu F, Balaban D,

Keywords: Pancreatic neuroendocrine tumour, ATRX, DAXX, ARX, PDX1,